Cargando…

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alves, Katia, Plested, Joyce S., Galbiati, Shirley, Chau, Gordon, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Smith, Kathy, Marcheschi, Alex, Pfeiffer, Susan, McFall, Heather, Smith, Gale, Glenn, Gregory M., Dubovsky, Filip, Mallory, Raburn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237325/ https://www.ncbi.nlm.nih.gov/pubmed/37271706 http://dx.doi.org/10.1016/j.vaccine.2023.05.051

Ejemplares similares

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
por: Mallory, Raburn M, et al.
Publicado: (2022)

Strong CD4(+) T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
por: Fries, Louis, et al.
Publicado: (2023)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
por: Heath, Paul T., et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
por: Dunkle, Lisa M., et al.
Publicado: (2021)

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials
por: Smith, Katherine, et al.
Publicado: (2023)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
por: Guebre-Xabier, Mimi, et al.
Publicado: (2020)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
por: Zhou, Pengcheng
Publicado: (2022)

Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study
por: Kulkarni, Prasad S., et al.
Publicado: (2023)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax(®)) COVID-19 Vaccination
por: Kim, Hyung Yoon, et al.
Publicado: (2022)

NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
por: Heath, Paul T, et al.
Publicado: (2022)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
por: Gorman, Matthew J., et al.
Publicado: (2021)

Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
por: Kim, Seontae, et al.
Publicado: (2023)

Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19
por: Mateo-Urdiales, Alberto, et al.
Publicado: (2023)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination
por: Alter, Galit, et al.
Publicado: (2021)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
por: Toback, Seth, et al.
Publicado: (2022)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
por: Patel, Nita, et al.
Publicado: (2023)

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M(™) vaccination
por: Gorman, Matthew J, et al.
Publicado: (2021)

NVX-CoV2373, un vaccin à sous-unités protéiques contre l’infection au SRAS-CoV-2
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients
por: Nowak, Alexandra, et al.
Publicado: (2023)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
por: Macías Saint-Gerons, Diego, et al.
Publicado: (2023)

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
por: Marchese, Anthony M., et al.
Publicado: (2023)

2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
por: Bennett, Chijioke, et al.
Publicado: (2023)

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial
por: Masuda, Taisei, et al.
Publicado: (2022)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid(®)) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty(®))
por: Nakayama, Tetsuo, et al.
Publicado: (2023)

Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals
por: Choi, Min Joo, et al.
Publicado: (2023)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
por: Plested, Joyce S., et al.
Publicado: (2023)

NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
por: Hielscher, Franziska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38au34smsnc36efp30ulgn24be